Rare disorder potentially indicated for kidney transplant Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

1 event

Dec 2018

Envarsus XR: FDA approved

ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Rare disorder potentially indicated for kidney transplant.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Envarsus XR

(tacrolimus)Orphan drug

Veloxis Pharmaceuticals, Inc.

12.1 Mechanism of Action Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin ...

Approved Dec 2018FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Rare disorder potentially indicated for kidney transplant.
Search all trials →

Search clinical trials for Rare disorder potentially indicated for kidney transplant →

Recent News & Research

No recent news articles indexed yet for Rare disorder potentially indicated for kidney transplant.
Search PubMed for Rare disorder potentially indicated for kidney transplant →

Browse all Rare disorder potentially indicated for kidney transplant news →

Specialist Network

No specialists currently listed for Rare disorder potentially indicated for kidney transplant.

View all Rare disorder potentially indicated for kidney transplant specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰